SpringWorks Therapeutics Inc logo

SpringWorks Therapeutics Inc

$ 30.52 +1.33 (+4.56%) 11:08 PM EST
P/E:
At Loss
P/B:
4.64
Market Cap:
$ 1.51B
Enterprise V:
$ 1.11B
Volume:
627.26K
Avg Vol (2M):
1.03M
Volume:
627.26K
Market Cap $:
1.51B
PE Ratio:
At Loss
Avg Vol (2-Month):
1.03M
Enterprise Value $:
1.11B
PB Ratio:
4.64
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

SpringWorks Therapeutics Inc
NAICS : 325412 SIC : 2834
100 Washington Boulevard, Stamford, CT, USA, 06902
Description
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Name Current Vs Industry Vs History
Cash-To-Debt 57.86
Equity-to-Asset 0.89
Debt-to-Equity 0.02
Debt-to-EBITDA -0.03
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score -4.67
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -62.5
3-Year EPS without NRI Growth Rate -21.5
3-Year FCF Growth Rate -60.2

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 45.7
9-Day RSI 48.52
14-Day RSI 50.22
6-1 Month Momentum % -49.75
12-1 Month Momentum % -60.78

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 9.8
Quick Ratio 9.8
Cash Ratio 9.58

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -30.4

Profitability Rank

Name Current Vs Industry Vs History
ROE % -54.58
ROA % -50.89
ROIC % -380.67
ROC (Joel Greenblatt) % -3178.11
ROCE % -54.08

Financials (Next Earnings Date:2022-11-04 Est.)

SWTX's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:SWTX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -4.67
Beta 0
Volatility % 77.18
14-Day RSI 50.22
14-Day ATR ($) 3.041896
20-Day SMA ($) 30.912
12-1 Month Momentum % -60.78
52-Week Range ($) 13.6 - 80.72
Shares Outstanding (Mil) 49.44

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

SpringWorks Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More